Resources from the same session
2282 - Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a Phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
Presenter: Brian Rini
Session: Proffered paper session - Genitourinary tumours, non prostate
Resources:
Abstract
Slides
Webcast
1286 - Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results
Presenter: Marine Gross-Goupil
Session: Proffered paper session - Genitourinary tumours, non prostate
Resources:
Abstract
Slides
Webcast
Proffered paper session - Genitourinary tumours, non prostate - Invited Discussant LBA31 and 863O
Presenter: Manuela Schmidinger
Session: Proffered paper session - Genitourinary tumours, non prostate
3575 - Pembrolizumab for High-Risk (HR) Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG): Phase 2 KEYNOTE-057 Trial
Presenter: Ronald de Wit
Session: Proffered paper session - Genitourinary tumours, non prostate
Resources:
Abstract
Slides
Webcast
3687 - Nivolumab (N) Alone or in Combination With Ipilimumab (I) in Patients (pts) With Platinum-Pretreated Metastatic Urothelial Carcinoma (mUC), Including the Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Expansion From CheckMate 032
Presenter: Jonathan Rosenberg
Session: Proffered paper session - Genitourinary tumours, non prostate
Resources:
Abstract
Slides
Webcast
Proffered paper session - Genitourinary tumours, non prostate - Invited Discussant LBA32
Presenter: Cora Sternberg
Session: Proffered paper session - Genitourinary tumours, non prostate
Resources:
Slides
Webcast